|
rs397517132
|
|
Colorectal Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The US Food and Drug Administration approved a liquid biopsy test for EGFR-activating mutations in patients with non-small-cell lung cancer as a companion diagnostic for therapy selection. ctDNA also allows for the identification of mutations selected by treatment such as EGFR T790M in non-small-cell lung cancer. ctDNA can also detect mutations such as KRAS G12V in colorectal cancer and BRAF V600E/V600K in melanoma.
|
30883505 |
2019 |
|
rs397517132
|
|
Colorectal Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Non-V600E BRAF mutations and EGFR signaling pathway in colorectal cancer.
|
30963570 |
2019 |
|
rs397517132
|
|
Colorectal Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E-Mutated Colorectal Cancer.
|
31566309 |
2019 |
|
rs397517132
|
|
Colorectal Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The US FDA approved a liquid biopsy test for EGFR activating mutations in patients with non-small cell lung cancer (NSCLC) as a companion diagnostic for therapy selection. ctDNA also allows for the identification of mutations selected by treatment such as EGFR T790M in NSCLC. ctDNA can also detect mutations such as KRAS G12V in colorectal cancer and BRAF V600E/V600K in melanoma.
|
30335711 |
2018 |
|
rs397517132
|
|
Colorectal Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Here, we investigate molecular responses upon single and multi-target treatments, over time, using BRAF(V600E) mutant colorectal cancer cells as a model system.
|
29970458 |
2018 |
|
rs397517132
|
|
Colorectal Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Further preclinical and clinical investigations are needed to clarify the role of non-V600E mutations in CRC.
|
30463788 |
2018 |
|
rs397517132
|
|
Colorectal Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
This study aimed to determine whether V600E mutant and wild type BRAF colorectal cancers exhibit distinct sensitivities to the dual BRAF inhibitor AZ304.
|
29755114 |
2018 |
|
rs397517132
|
|
Colorectal Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
In this study, we explored the effect of combined use of dabrafenib, a BRAF inhibitor, and cetuximab, an EGFR inhibitor, on BRAF(V600E)-mutant CRC stem cells and its possible mechanisms.
|
29534162 |
2018 |
|
rs397517132
|
|
Colorectal Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
<i>BRAF</i> V600E colorectal cancers are insensitive to RAF inhibitor monotherapy due to feedback reactivation of receptor tyrosine kinase signaling.
|
28951457 |
2017 |
|
rs397517132
|
|
Colorectal Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
We provide a global assessment of gene expression motifs that differentiate BRAF V600E subtypes from other colorectal cancers.
|
27354468 |
2017 |
|
rs397517132
|
|
Colorectal Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Concomitant with such properties, EBI-907 exhibits potent and selective cytotoxicity against a broader range of BRAF(V600E)-dependent cell lines including certain colorectal cancer cell lines with innate resistance to Vemurafenib.
|
26810733 |
2016 |
|
rs397517132
|
|
Colorectal Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Sporadic MSI CRC often harbours BRAF(V600E); however, no consistent data exist regarding targeted treatment approaches in BRAF(wt) MSI CRC.
|
26001389 |
2016 |
|
rs397517132
|
|
Colorectal Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
We evaluated miR-31-5p expression and gene mutations [KRAS (codon 61 or 146), NRAS (codon 12, 13, or 61), and BRAF (V600E)] in the EGFR downstream pathway in 102 CRC patients harboring KRAS (codon 12 or 13) wild-type who were treated with anti-EGFR therapeutics.
|
25472647 |
2015 |
|
rs397517132
|
|
Colorectal Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Approximately 5-10% of metastatic colorectal cancers harbor a BRAF-V600E mutation, which is correlated with resistance to EGFR-targeted therapies and worse clinical outcome.
|
26160848 |
2015 |
|
rs397517132
|
|
Colorectal Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
In marked contrast to the results seen in patients with BRAF V600E-mutant melanoma, single-agent vemurafenib did not show meaningful clinical activity in patients with BRAF V600E mutant CRC.
|
26460303 |
2015 |
|
rs397517132
|
|
Colorectal Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
These findings support BGB-283 as a potent antitumor drug candidate with clinical potential for treating colorectal cancer harboring BRAF(V600E) mutation.
|
26208524 |
2015 |
|
rs397517132
|
|
Colorectal Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants.
|
25714871 |
2015 |
|
rs397517132
|
|
Colorectal Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
A point mutation (V600E) in the BRAF oncogene is a prognostic biomarker and may predict for nonresponse to anti-EGFR antibody therapy in patients with colorectal carcinoma.
|
23657789 |
2013 |
|
rs397517132
|
|
Colorectal Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Detection of the BRAF V600E </span>mutation in colorectal cancer by immunohistochemistry is a viable alternative to molecular methods.
|
23650027 |
2013 |
|
rs397517132
|
|
Colorectal Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Here, we discuss the current commonly used predictive pharmacogenetic biomarkers in clinical oncology molecular testing: BRAF V600E for vemurafenib in melanoma; EML4-ALK for crizotinib and EGFR for erlotinib and gefitinib in non-small-cell lung cancer; KRAS against the use of cetuximab and panitumumab in colorectal cancer; ERBB2 (HER2/neu) for trastuzumab in breast cancer; BCR-ABL for tyrosine kinase inhibitors in chronic myeloid leukemia; and PML/RARα for all-trans-retinoic acid and arsenic trioxide treatment for acute promyelocytic leukemia.
|
22845480 |
2012 |
|
rs397517132
|
|
Colorectal Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Thus, large-scale KRAS mutation screening is needed for efficient patient management and in the future metastatic colorectal cancer genotyping might also include the detection of the BRAF V600E mutation, which is a very strong negative prognostic factor in colorectal cancer.
|
21516079 |
2011 |
|
rs397517132
|
|
Colorectal Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Real-time polymerase chain reaction identifies the most common BRAF mutation, V600E, in frozen or paraffin-embedded colorectal cancer tissue.
|
20670148 |
2010 |
|
rs397517132
|
|
Colorectal Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Double-hit therapies aimed at simultaneous inhibition of epidermal growth factor receptor and BRAF warrant exploration in CR</span>C patients carrying the V600E oncogenic mutation.
|
19001320 |
2008 |
|
rs909797662
|
|
Colorectal Carcinoma
|
|
0.040 |
GeneticVariation
|
BEFREE |
However, among the various <i>KRAS</i> mutations, that which encodes the G13D mutant protein (KRAS<sup>G13D</sup>) behaves differently; for unknown reasons, KRAS<sup>G13D</sup> CRC patients benefit from the EGFR-blocking antibody cetuximab.
|
31551296 |
2019 |
|
rs909797662
|
|
Colorectal Carcinoma
|
|
0.040 |
GeneticVariation
|
BEFREE |
These results reveal that KRAS G13D is responsive to neurofibromin-stimulated hydrolysis and suggest that a subset of <i>KRAS</i> G13-mutated colorectal cancers that are neurofibromin-competent may respond to EGFR therapies.
|
31611389 |
2019 |